Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations

eClinicalMedicine · 19 authors, 22 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This position paper summarizes recommendations from a multidisciplinary discussion on addressing cancer care disparities for transgender and gender-diverse individuals, identifying research promotion as a priority action to mitigate these disparities.

Full summary

787 CHARS

The paper presents the 'Assisi Recommendations' from a 2-day multidisciplinary ethics discussion by the Italian Association of Medical Oncology (AIOM). It outlines barriers in cancer prevention and treatment for transgender and gender-diverse people, attributing worse clinical outcomes to disadvantages in social-economic determinants of health. The recommendations address aspects of the cancer care experience for this population, with a primary emphasis on promoting research to generate new evidence and collect prospective data. The paper calls for multi-level interventions, holistic approaches, and trans-disciplinary collaboration to improve equitable care. It advocates for improved medical education, inclusive healthcare policies, and actions to facilitate healthcare access.

STUDY TYPE

guidelines

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10590834

Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations

eClinicalMedicine

READ THE FULL PAPER

ABSTRACT

Summary Transgender and gender-diverse individuals experience substantial health disparities across the cancer care continuum. Despite well recognized unique healthcare needs, there are barriers in accessing cancer prevention and treatment services, influenced by disadvantages in key social-economic determinants of health which result in worse clinical outcomes, as compared to the general population. The Italian Association of Medical Oncology (AIOM) acknowledges the critical relevance of this issue. The “ Assisi Recommendations ” here summarize the outcomes of the “AIOM Oncology Ethics Day” dedicated to gender differences in oncology and cancer care of transgender and gender-diverse people. The recommendations generated during a 2-day multidisciplinary discussion address the various aspects of cancer care experience of transgender and gender-diverse people. The promotion of research in this field, through the generation of new evidence and the collection of prospective data, has been identified as a priority action to mitigate these disparities. By acknowledging the challenges of cancer care in transgender and gender-diverse people and recognizing the need for dedicated policy and clinical recommendations, AIOM demonstrates its commitment to improving the health and well-being of all patients with cancer, regardless of their gender identity or any other personal or social circumstances, as part of health-for-all societal vision.

CITATION EXPORT

Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani et al.. Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations. eClinicalMedicine. (2023). https://doi.org/10.1016/j.eclinm.2023.102277

AUTHORS

19 · 22 CENTRES

Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, Rosalba Miceli, Massimo Massagrande, Federica Morano, Nicla La Verde, Davide Dalu, Rossana Berardi, Silvia Marsoni, Matteo Lambertini, Bianca Iula, Eva Carieri, Manlio Converti, Massimo Di Maio, Giordano Domenico Beretta, Francesco Perrone, Filippo Pietrantonio, Saverio Cinieri

aMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan 21033, Italy
bWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
cEuropean Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
dDepartment of Oncology and Hemato-oncology (DIPO), University of Milan, Milan, Italy
eDepartment of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan 21033, Italy
fELMA Research, Milan, Italy
gDepartment of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
hOncology Clinic, Università Politecnica delle Marche, AOU delle Marche, Ancona, Italy
iIFOM - the FIRC Institute of Molecular Oncology, Milan, Italy
jDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy
kDepartment of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy
lACET - Associazione per la Cultura e l’etica Transgenere (Association for Transgender Culture and Ethics), Milan, Italy Degree: N/A
mIndependent Researcher, Italy Degree: N/A
nAMIGAY Aps - Associazione Italiana Medici e Personale Sanitario, LGBTQIA+ e Friendly (Italian Association of LGBTQIA+ Medical care Providers), Italy
oDepartment of Oncology, University of Turin, A.O. Ordine Mauriziano, Turin, Italy
pNational Secretary of the Italian Association of Medical Oncology (AIOM), Italy
qUOC Oncologia Medica, ASL Pescara P.O., Pescara, Italy
rNational President of the Italian Foundation of Medical Oncology (Fondazione AIOM), Italy
sClinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
tPresident-elect of the Italian Association of Medical Oncology (AIOM), Italy
uMedical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Italy
vNational President of the Italian Association of Medical Oncology (AIOM), Italy